Table 2.

Clinical characteristics of the study population based on different defined intervals of PCR repositivity

Variable	First infection			Second infection
	Minimum interval of PCR repositivity			Minimum interval of PCR repositivity
	45 days	60 days	90 days	45 days	60 days	90 days
	(n=30)	(n=23)	(n=14)	(n=29)*	(n=23)	(n=14)
Disease severity
Asymptomatic	13 (43.3%)	12 (52.2%)	8 (57.1%)	16 (55.2%)	12 (52.2%)	5 (35.7%)
Mild illness	15 (33.3%)	9 (39.1%)	4 (28.6%)	9 (31%)	7 (30.4%)	5 (35.7%)
Mild pneumonia	1 (3.3%)	1 (4.3%)	1 (7.1%)	0	0	0
Severe pneumonia	1 (3.3%)	1 (4.3%)	1 (7.1%)	4 (13.8%)	4 (17.4%)	4 (28.6%)
Reason for testing
Close contact testing	13 (43.3%)	12 (52.2%)	8 (57.1%)	6 (20.7%)	5 (21.7%)	4 (28.6%)
Hospitalisation screening	5 (16.7%)	4 (17.4%)	3 (21.4%)	7 (24.1%)	6 (26.1%)	5 (35.7%)
Suspected COVID-19	12 (40%)	7 (30.4%)	3 (21.4%)	6 (20.7%)	5 (21.7%)	4 (28.6%)
Travel screening	1 (3.3%)	0	0	10 (34.5%)	7 (30.4%)	1 (7.1%)
Symptoms
Abdominal pain	2 (4%)	1 (3.1%)	1 (5%)	0	0	0
Cough	4 (8.2%)	4 (12.5%)	3 (15%)	8 (20.5%)	8 (21.6%)	7 (21.9%)
Diarrhoea	2 (4%)	2 (6.3%)	2 (10%)	0	0	0
Fever	16 (32.6%)	11 (34.4%)	6 (30%)	12 (30.8%)	10 (27%)	8 (25%)
Headache	2 (4%)	2 (6.3%)	1 (5%)	1 (2.6%)	1 (2.7%)	1 (3.1%)
Loss of smell	4 (8.2%)	1 (3.1%)	0	1 (2.6%)	1 (2.7%)	1 (3.1%)
Loss of taste	4 (8.2%)	1 (3.1%)	0	1 (2.6%)	1 (2.7%)	1 (3.1%)
Myalgia	4 (8.2%)	3 (9.4%)	3 (15%)	1 (2.6%)	1 (2.7%)	1 (3.1%)
Rhinorrhoea	4 (8.2%)	3 (9.4%)	1 (5%)	8 (20.5%)	8 (21.6%)	7 (21.9%)
Shortness of breath	3 (6.1%)	2 (6.3%)	2 (10%)	3 (7.7%)	3 (8.1%)	3 (9.4%)
Sore throat	3 (6.1%)	2 (6.3%)	1 (5%)	3 (7.7%)	3 (8.1%)	2 (6.3%)
Vomiting	1 (2%)	0	0	1 (2.6%)	1 (2.7%)	1 (3.1%)
Hospitalisation	5 (16.7%)	4 (17.4%)	3 (21.4%)	6 (20.7%)	5 (21.7%)	5 (35.7%)
Length of stay in days (median, IQR)	9 (5.75–13)	9 (7.25–11)	8 (6.5–9)	6 (3–6)	6 (3–6)	6 (3–6)

*Clinical data for one patient is missing.